Infliximab biosimilar (Shanghai Biomabs)

Product Name :
Infliximab biosimilar (Shanghai Biomabs)

Search keywords :
Infliximab

drugId :
null

Target Vo:
Tumor necrosis factor α

Target Vo Short Name :
TNFα

Moa_Name:
Tumor necrosis factor α inhibitors

First Approval Country :
Mainland China

First Approval Date Filter:
2021

Origin Company_Name :
Shanghai Biomabs Pharmaceuticals Co Ltd

Active Company_Name :
Shandong Kexing Bio-Products Co Ltd

Active Indication_Name:
Pediatric Crohn’s disease

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
SOD2 Antibody (YA670)
EGFR Antibody
ADAMTS5 Antibody: ADAMTS5 Antibody is an unconjugated, approximately 102 kDa, rabbit-derived, anti-ADAMTS5 polyclonal antibody. ADAMTS5 Antibody can be used for: WB, ELISA, IHC-P expriments in human, mouse, rat, and predicted: dog, pig, cow, horse, rabbit background without labeling.

Author: Betaine hydrochloride

Related Posts